Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545943 | 1.00 | CYP11B1 (0.42) | CYP11B1GRM2PARP1MMP2MMP9 | |
| SCHEMBL1171911 | 0.83 | CYP11B1 (0.37) | CYP11B1GRM2PARP1MMP2MMP9 | |
| SCHEMBL12881275 | 0.82 | ICAM1 (0.37) | CYP11B1GRM2MMP2MMP9MMP8 | |
| SCHEMBL1172004 | 0.82 | ICAM1 (0.37) | CYP11B1GRM2MMP2MMP9MMP8 | |
| SCHEMBL2455016 | 0.80 | CYP11B1 (0.40) | CYP11B1GRM2PARP1CHRNB2CHRNA4 | |
| SCHEMBL30228073 | 0.79 | KDM1A (0.43) | CYP11B1MAOA | |
| SCHEMBL1257274 | 0.79 | KDM1A (0.43) | CYP11B1MAOA | |
| SCHEMBL15291845 | 0.79 | NPC1 (0.33) | CYP11B1MAOADYRK1ANPC1POLB | |
| SCHEMBL487301 | 0.77 | TSHR (0.41) | MAOADYRK1APOLB | |
| SCHEMBL23910168 | 0.76 | TSHR (0.37) | CYP11B1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| EP-3589628-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240229063-A1 | TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240002415-A1 | PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-7576089-B2 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION | 2009-08-18 | — | — | US | disclosed |
| EP-1696919-A4 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1696919-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2006-09-06 | — | — | EP | disclosed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | PFIZER INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005060665-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | CYP11B1 1683/4885GRM2 404/4885PARP1 573/4885 |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | CYP11B1 1884/4885GRM2 3/4885PARP1 4766/4885 |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | CCR2, CCR5, CXCR3 | CYP11B1 1745/4885GRM2 687/4885PARP1 995/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CYP11B1 130/4885GRM2 4721/4885PARP1 3762/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | CYP11B1 1884/4885GRM2 3/4885PARP1 4766/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | CYP11B1 3555/4885GRM2 1736/4885PARP1 1946/4885 |
| US-20240002415-A1 | PHOSPHINE REAGENTS FOR AZINE FLUOROALKYLATION | PTPN3, PHOSPHO1, SKIC3 | CYP11B1 4620/4885GRM2 2069/4885PARP1 2427/4885 |
| US-12162860-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CYP11B1 130/4885GRM2 4721/4885PARP1 3762/4885 |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | CYP11B1 1596/4885GRM2 2004/4885PARP1 3447/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | CYP11B1 336/4885GRM2 4476/4885PARP1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.